These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33341406)

  • 21. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eradication of
    Akkerman-Nijland AM; Yousofi M; Rottier BL; Van der Vaart H; Burgerhof JGM; Frijlink HW; Touw DJ; Koppelman GH; Akkerman OW
    Ther Adv Respir Dis; 2020; 14():1753466620905279. PubMed ID: 32046620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
    Tappenden P; Harnan S; Uttley L; Mildred M; Carroll C; Cantrell A
    Health Technol Assess; 2013 Dec; 17(56):v-xvii, 1-181. PubMed ID: 24290164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
    Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR;
    Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nebulised anti-pseudomonal antibiotics for cystic fibrosis.
    Ryan G; Mukhopadhyay S; Singh M
    Cochrane Database Syst Rev; 2003; (3):CD001021. PubMed ID: 12917897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF).
    Harrison MJ; McCarthy M; Fleming C; Hickey C; Shortt C; Eustace JA; Murphy DM; Plant BJ
    J Cyst Fibros; 2014 Dec; 13(6):692-8. PubMed ID: 24815094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.
    Clancy JP; Dupont L; Konstan MW; Billings J; Fustik S; Goss CH; Lymp J; Minic P; Quittner AL; Rubenstein RC; Young KR; Saiman L; Burns JL; Govan JR; Ramsey B; Gupta R;
    Thorax; 2013 Sep; 68(9):818-25. PubMed ID: 23749840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbiological and immunologic considerations with aerosolized drug delivery.
    LiPuma JJ
    Chest; 2001 Sep; 120(3 Suppl):118S-123S. PubMed ID: 11555566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K
    Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
    Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
    J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.
    Sommerwerck U; Virella-Lowell I; Angyalosi G; Viegas A; Cao W; Debonnett L
    Curr Med Res Opin; 2016 Nov; 32(11):1789-1795. PubMed ID: 27435882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Bilton D; Pressler T; Fajac I; Clancy JP; Sands D; Minic P; Cipolli M; Galeva I; Solé A; Quittner AL; Liu K; McGinnis JP; Eagle G; Gupta R; Konstan MW;
    J Cyst Fibros; 2020 Mar; 19(2):284-291. PubMed ID: 31451351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
    Ryan G; Jahnke N; Remmington T
    Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study.
    Mainz JG; Schädlich K; Schien C; Michl R; Schelhorn-Neise P; Koitschev A; Koitschev C; Keller PM; Riethmüller J; Wiedemann B; Beck JF
    Drug Des Devel Ther; 2014; 8():209-17. PubMed ID: 24596456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
    Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
    Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.
    Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG
    Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Administration of aerosolized antibiotics in cystic fibrosis patients.
    Moss RB
    Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Quittner AL; Buu A
    Pediatr Pulmonol; 2002 Apr; 33(4):269-76. PubMed ID: 11921456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.